0001209191-21-051441.txt : 20210813 0001209191-21-051441.hdr.sgml : 20210813 20210813171346 ACCESSION NUMBER: 0001209191-21-051441 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210708 FILED AS OF DATE: 20210813 DATE AS OF CHANGE: 20210813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galante Joseph C CENTRAL INDEX KEY: 0001632384 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 211173327 MAIL ADDRESS: STREET 1: 111 TENTH AVENUE STREET 2: SUITE 200 CITY: NASHVILLE STATE: TN ZIP: 37203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-08 0 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001632384 Galante Joseph C 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203 1 0 0 0 Common Stock 2021-07-08 4 P 0 142 3.18 A 32559 D Common Stock 2021-07-09 4 P 0 142 3.13 A 32701 D Common Stock 2021-07-12 4 P 0 142 3.33 A 32843 D Common Stock 2021-07-13 4 P 0 142 3.48 A 32985 D Common Stock 2021-07-14 4 P 0 142 3.33 A 33127 D Common Stock 2021-07-15 4 P 0 142 3.27 A 33269 D Common Stock 2021-07-16 4 P 0 142 3.28 A 33411 D Common Stock 2021-07-19 4 P 0 142 3.23 A 33553 D Common Stock 2021-07-20 4 P 0 142 3.24 A 33695 D Common Stock 2021-07-21 4 P 0 142 3.26 A 33837 D Common Stock 2021-07-22 4 P 0 142 3.36 A 33979 D Common Stock 2021-07-23 4 P 0 142 3.35 A 34121 D Common Stock 2021-07-26 4 P 0 142 3.39 A 34263 D Common Stock 2021-07-27 4 P 0 142 3.39 A 34405 D Common Stock 2021-07-28 4 P 0 142 3.42 A 34547 D Common Stock 2021-07-29 4 P 0 142 3.42 A 34689 D Common Stock 2021-07-30 4 P 0 142 3.31 A 34831 D The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Joseph C. Galante by /s/ John Hamm as attorney-in-fact 2021-08-13